You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 13, 2025

List of Excipients in API pralsetinib


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing pralsetinib

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
Genentech Inc GAVRETO pralsetinib 50242-210 ANHYDROUS CITRIC ACID 2036-11-01
Genentech Inc GAVRETO pralsetinib 50242-210 HYDROXYPROPYL CELLULOSE 2036-11-01
Genentech Inc GAVRETO pralsetinib 50242-210 MAGNESIUM STEARATE 2036-11-01
Genentech Inc GAVRETO pralsetinib 50242-210 SODIUM BICARBONATE 2036-11-01
Rigel Pharmaceuticals Inc GAVRETO pralsetinib 71332-006 ANHYDROUS CITRIC ACID 2036-11-01
Rigel Pharmaceuticals Inc GAVRETO pralsetinib 71332-006 HYDROXYPROPYL CELLULOSE 2036-11-01
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Get Started Free

Detailed excipient profiles for pralsetinib

Excipient focus: ALCOHOL

Excipient focus: AMMONIA

Excipient focus: ANHYDROUS CITRIC ACID

Excipient focus: BUTYL ALCOHOL

Excipient focus: FD&C BLUE NO. 1

Excipient focus: HYDROXYPROPYL CELLULOSE

Excipient focus: HYPROMELLOSE 2910

Excipient focus: ISOPROPYL ALCOHOL

Excipient focus: MAGNESIUM STEARATE

Excipient focus: MICROCRYSTALLINE CELLULOSE 102

Excipient focus: POLYVINYL ALCOHOL

Excipient focus: POTASSIUM HYDROXIDE

Excipient focus: PROPYLENE GLYCOL

Excipient focus: SHELLAC

Excipient focus: SODIUM BICARBONATE

Excipient focus: STARCH, CORN

Excipient focus: TITANIUM DIOXIDE

Excipient focus: WATER

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
 NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links